"Success in the clinic for Alzheimer's, though, has long eluded Lilly. Aside from its failed BACE effort, there was a disastrous effort with a gamma secretase drug, followed by the high-profile Phase III flop for solanezumab, once billed as a key test of the amyloid beta theory, which proposes that a reduction in the toxic protein clusters can ameliorate the memory-destroying disease that afflicts millions of people. Lilly, though, believes it saw a strong enough sign of success in a subpopulation to justify a second Phase III effort for solanezumab. And it's taken some of the lessons learned over the years to design a Phase II/III BACE trial with better odds for success." ref Fiercebiotech
Thanks. Have to agree it sounds almost too good to be true, but it sure fits with a line of thinking around how LYMPRO will/should be used(RUO). If it is AMBS it is a brilliant catch.
Dude, have looked and found no links...it would be great news if true....but?
I own this stock because I think history shows these guys know how to make money. They cleaned house, a painful but needed exercise. I am thinking Q4 resets it all.
Watson, a benefit of hard science is one can predict with confidence approaching certainty. You suggest the same for AMBS finance, hope you are right this time. Lympro looks to be a tool which might be the AD genie out of the bottle for Pharma, is that the Roche connection?
Been waiting for years and would like to see real products, data and solutions.
All the best.
My guess is the volumes will surprise to the upside. More PR due on LYMPRO, which could happen any time. Too much leverage to just let time pass by both retailers and specs. Curious choice for Orphan PR timing, obviously GC planned this sequence w/guesses around FDA action dates.
This is a well known Irish folk song....the major happy theme is .."Good night, and joy be to you all"...we have waited a long time for real and good news, perhaps this is the end of the beginning. All the best.
Yes, ladies and gentlemen the Red Sox have dominated the Yankees yet again. Wait, wait...it looks like Derick Jeter's platinum wheel cahir has been stolen, he normally leaves it parked in one of the empty $2500 seats near 3rd base. No wait, it's A-Rod there with the wheelchair, he selling it for drugs behind the dug out. What ever happened to the best baseball team money could buy? The dynasty is a sad shadow of it's former self absorbed phoney as it gets self.....so friggen sad.
silver bullet....."MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently pursued. Further applications for MANF may include Alzheimer's disease, traumatic brain injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation"
Bottom of the 9th, man on third, man on second...NYY & SOX tied up at 3 ...Red Sox up...the count to "big Poppi" is 3 and 2 ...he stretches and ...........BOOOOOOOOOOOOOMMMM, a walk off...
Should've used Lympro..
."The setback for Alzheimer's drug gantenerumab is especially disappointing, since there had been hopes that giving it in the final Phase III study to patients with so-called prodromal disease, or pre-dementia, would produce a better outcome.
Many scientists believe the best hope for treating Alzheimer's lies in giving drugs at this earlier stage, before patients' brains are wrecked
Huh, OK ...based on your assessment of trades by specific individuals or just in general. BTW, not questioning your judgement. We are due (IMO) and I support a moving upward message . The bigger the better and, in fact, massive is fine.
dol is your opinion based on observation, facts, linked events? ...hope you are right. Some trigger event (good or bad) is in the air.
This is an excellent observation. In fact some have made it a point in their incoming PR. A guy who starts AMGEN and has more money that the pope will not intentionaly mislead, legalities aside.